We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
122 13 0 TKTX
Emcee:  trevor john wilkinson Type:  Unmoderated
Anybody know this company?

Best regards,
trevor Wilkinson
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
122Slime. Ex-Transkaryotic Chief Pays $1.2 Million in SEC Suit (Update1) By Davrkrw-7/11/2008
121Genzyme, TKT end disputes Once-bitter rivals drop patent battles, forge drug-sim1-10/9/2003
120Transkaryotic to lay off 80 Decision boosts battered shares; staff down to 34sim1-3/20/2003
119Career U-turn brings ex-counsel back to TKT When Astrue left the biotech firmsim1-2/26/2003
118TKT chief quits; new CEO vows to end slide By Naomi Aoki, Globe Staff, 2/12/2sim1-2/13/2003
117UPDATE: TKTX loses AMGN appeal Well, there goes one investment thesis. ReplacLondo-1/7/2003
116<i>I also meant I did not know whose hand is on the conversion trigger. DoLondo-1/6/2003
115Aventis. Thanks for the correction. By unclear, I did mean we don't know hkeokalani'nui-1/6/2003
114<i>glaxo would have to manufacture it over there.</i> I thought AveLondo-1/6/2003
113On the market in the EC, TKTX's Fabry drug is in deep trouble in the US regukeokalani'nui-1/6/2003
112I don't follow this one, so I am not able to even offer an inexpert opinion.tuck-1/6/2003
111Has anyone heard if their products are probably going to receive FDA approval ortsq-1/6/2003
110From the FDA's website: >>DATE AND TIME: September 25, 26, and 27, 8:tuck-9/6/2002
10908:59 ET TKTX Transkaryotic named Bottom Line Action Idea at Cowen (40.88) IRWIN JAMES FRANKEL-4/22/2002
108FMR Corp., Fidelity Parent, Reports 10.3% Stake In Sybron WASHINGTON -(Dow Jonemopgcw-4/10/2002
107Grim waiting game Patients with rare Fabry disease fear drug won't be OKrkrw-2/13/2002
106Transkaryotic started at 'outperform' at Morgan Keegan. eomSouze-1/28/2002
105TKT Announces Date of Fourth Quarter 2001 Financial Results and Conference Call Souze-1/28/2002
104TKT Granted Orphan Drug Status for Hunter Syndrome Treatment in Both Europe And Souze-1/3/2002
103TKT Announces Victory in Genzyme Patent Litigation - No Infringement; Trial CancSouze-12/17/2001
102Friday December 14, 3:39 pm Eastern Time Press Release SOURCE: Genzyme General GIRWIN JAMES FRANKEL-12/14/2001
101TKT and Aventis Receive Recommendation for Marketing Approval of Dynepo(TM) in ESouze-12/12/2001
100TKT Announces Favorable Outcome in Markman Hearing in Replagal(TM) Patent LitigaSouze-11/29/2001
99TKT Awarded U.S. Patent Relating to Protein Production and Delivery For Gene TheSouze-10/23/2001
98TKTX upped to 'Strong Buy' by SG Cowen. eomSouze-10/23/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):